[2-(5-bromo-pyrimidin-2-yloxy)ethyl]-dimethylamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: [2-(5-bromo-pyrimidin-2-yloxy)ethyl]-dimethylamine
• 英文别名: 2-((5-Bromopyrimidin-2-yl)oxy)-N,N-dimethylethanamine；2-(5-bromopyrimidin-2-yl)oxy-N,N-dimethylethanamine
• 化学式: C₈H₁₂BrN₃O
• 分子量: 246.107
• InChiKey: VGJITRRQYVONDY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-[(R)-4-(2-imidazo[4,5-b]pyridin-3-yl-acetyl)-3-methyl-piperazin-1-yl]-2-trifluoromethyl-thiazole-4-carboxylic acid 、 [2-(5-bromo-pyrimidin-2-yloxy)ethyl]-dimethylamine 在 二(三叔丁基膦)钯 、 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.25h， 生成 1-((R)-4-{4-[2-(2-dimethylamino-ethoxy)pyrimidin-5-yl]-2-trifluoromethyl-thiazol-5-yl}-2-methylpiperazin-1-yl)-2-imidazo[4,5-b]pyridin-3-ylethanone
  参考文献：
  名称：

  Discovery and In Vivo Evaluation of ACT-660602: A Potent and Selective Antagonist of the Chemokine Receptor CXCR3 for Autoimmune Diseases

  摘要：

  DOI：

  10.1021/acs.jmedchem.2c00675
• 作为产物：
  描述：

  N,N-二甲基乙醇胺 、 5-溴-2-氯嘧啶 在 sodium hydride 作用下， 以 四氢呋喃 、 mineral oil 为溶剂， 反应 2.25h， 以69%的产率得到[2-(5-bromo-pyrimidin-2-yloxy)ethyl]-dimethylamine
  参考文献：
  名称：

  [EN] 1-(PIPERAZIN-1-YL)-2-([1,2,4]TRIAZOL-1-YL)-ETHANONE DERIVATIVES
  [FR] DÉRIVÉS DE 1-(PIPÉRAZIN-1-YL)-2-([1,2,4]TRIAZOL-1-YL)-ÉTHANONE

  摘要：

  本发明涉及公式（I）中的化合物，其中X、Y、R1、R2、R3、R4和R5如描述中所述；以及其药学上可接受的盐，以及将这些化合物用作药物，特别是作为CXCR3受体调节剂。

  公开号：

  WO2015011099A1

文献信息

• [EN] 1-(PIPERAZIN-1-YL)-2-([1,2,4]TRIAZOL-1-YL)-ETHANONE DERIVATIVES<br/>[FR] DÉRIVÉS DE 1-(PIPÉRAZIN-1-YL)-2-([1,2,4]TRIAZOL-1-YL)-ÉTHANONE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2015011099A1

  公开（公告）日：2015-01-29

  The invention relates to compounds of Formula (I) wherein X, Y, R1, R2, R3, R4 and R5 are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments, especially as modulators of the CXCR3 receptor.

  本发明涉及公式（I）中的化合物，其中X、Y、R1、R2、R3、R4和R5如描述中所述；以及其药学上可接受的盐，以及将这些化合物用作药物，特别是作为CXCR3受体调节剂。
• [EN] [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS [1,2,4]TRIAZOLO[1,5-A]PYRIDINE ET [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE ET LEUR UTILISATION
  申请人：CANCER REC TECH LTD

  公开号：WO2009047514A1

  公开（公告）日：2009-04-16

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain triazolo compounds (referred to herein as TAZ compounds), and especially certain [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds, which, inter alia, inhibit AXL receptor tyrosine kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit AXL receptor tyrosine kinase function, and in the treatment of diseases and conditions that are mediated by AXL receptor tyrosine kinase, that are ameliorated by the inhibition of AXL receptor tyrosine kinase function, etc., including proliferative conditions such as cancer, etc.

  本发明一般涉及治疗化合物领域，更具体地涉及某些三唑化合物（以下简称为TAZ化合物），特别是某些[1,2,4]三唑并[1,5-a]吡啶和[1,2,4]三唑并[1,5-c]嘧啶化合物，这些化合物等等，可以抑制AXL受体酪氨酸激酶功能。本发明还涉及包括这些化合物的药物组合物，以及使用这些化合物和组合物，无论是体外还是体内，来抑制AXL受体酪氨酸激酶功能，并用于治疗由AXL受体酪氨酸激酶介导的疾病和病况，通过抑制AXL受体酪氨酸激酶功能得到缓解的疾病和病况等，包括增生性疾病如癌症等。
• Pyridylfurans and pyrroles as Raf kinase inhibitors
  申请人：SmithKline Beechum P.L.C.

  公开号：US07297694B2

  公开（公告）日：2007-11-20

  Compounds and their use as pharmaceuticals particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy.

  化合物及其作为药物的使用，特别是作为Raf激酶抑制剂，用于治疗神经创伤性疾病、癌症、慢性神经退行性疾病、疼痛、偏头痛和心肌肥厚。
• [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use
  申请人：Cancer Research Technology Limited

  公开号：US20140155594A1

  公开（公告）日：2014-06-05

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain triazolo compounds (referred to herein as TAZ compounds), and especially certain [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds, which, inter alia, inhibit AXL receptor tyrosine kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit AXL receptor tyrosine kinase function, and in the treatment of diseases and conditions that are mediated by AXL receptor tyrosine kinase, that are ameliorated by the inhibition of AXL receptor tyrosine kinase function, etc., including proliferative conditions such as cancer, etc.

  本发明涉及治疗化合物领域，更具体地涉及某些三唑化合物（在此称为TAZ化合物），特别是某些[1,2,4]三唑并[1,5-a]吡啶和[1,2,4]三唑并[1,5-c]嘧啶化合物，其中包括抑制AXL受体酪氨酸激酶功能的化合物。本发明还涉及包括这些化合物的制药组合物，以及使用这些化合物和组合物在体内外抑制AXL受体酪氨酸激酶功能，并用于治疗由AXL受体酪氨酸激酶介导的疾病和病症，通过抑制AXL受体酪氨酸激酶功能得到缓解的疾病和病症，包括增生性疾病如癌症等。
• [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use
  申请人：Pavé Grégoire Alexandre

  公开号：US08431596B2

  公开（公告）日：2013-04-30

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain triazolo compounds (referred to herein as TAZ compounds), and especially certain [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds, which, inter alia, inhibit AXL receptor tyrosine kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit AXL receptor tyrosine kinase function, and in the treatment of diseases and conditions that are mediated by AXL receptor tyrosine kinase, that are ameliorated by the inhibition of AXL receptor tyrosine kinase function, etc., including proliferative conditions such as cancer, etc.

  本发明一般涉及治疗化合物领域，更具体地涉及某些三唑化合物（以下简称TAZ化合物），尤其是某些[1,2,4]三唑并[1,5-a]吡啶和[1,2,4]三唑并[1,5-c]嘧啶化合物，它们可以抑制AXL受体酪氨酸激酶功能。本发明还涉及包含这种化合物的制药组合物，并且在体内外使用这种化合物和组合物来抑制AXL受体酪氨酸激酶功能，治疗由AXL受体酪氨酸激酶介导的疾病和病状，通过抑制AXL受体酪氨酸激酶功能改善这些疾病和病状，包括增生性疾病如癌症等。